Plasma CD105, TGFbeta-1, TGFbeta-3 and the ligand/receptor complexes in children with acute lymphoblastic leukaemia.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72546
Title:
Plasma CD105, TGFbeta-1, TGFbeta-3 and the ligand/receptor complexes in children with acute lymphoblastic leukaemia.
Authors:
Al-Mowallad, Abdul Fattah; Carr, Trevor F; Al-Qouzi, Abdullah; Li, Chenggang; Byers, Richard J; Kumar, Shant
Abstract:
The role of angiogenesis in solid tumours is well recognised, but its importance in haematological malignancies is less well understood. In leukaemia, mainly the determination of microvascular density utilising immunohistochemistry in the bone marrow trephines and the measurement of soluble angiogenic factors have led to the recognition that angiogenesis may be important in leukaemia as well. In this study, the soluble form of the endothelial cell activation/proliferation (i.e., angiogenesis) marker CD105 and its ligands TGFbeta-1 and -3, as well as the ligand/receptor complexes in plasma from children with acute lymphoblastic leukaemia (ALL) were quantified. The plasma level of CD105 was significantly higher in patients with common ALL compared to controls, while the TGFbeta-3 level was lower in patients. Neither the CD105 or TGFbeta-3 levels were of prognostic value, nor did they correlate with any of the known prognostic indicators, such as white blood cell counts. There were no significant differences between the plasma levels of any of the other parameters, such as TGFbeta-1 or the ligand receptor complexes, in children with leukaemia compared to controls. Our results support the role of angiogenesis in leukaemia and suggest that anti-angiogenesis may be a therapeutic target in leukaemia.
Affiliation:
Division of Laboratory and Regenerative Medicine, The University of Manchester, UK.
Citation:
Plasma CD105, TGFbeta-1, TGFbeta-3 and the ligand/receptor complexes in children with acute lymphoblastic leukaemia., 26 (1B):543-7 Anticancer Res.
Journal:
Anticancer Research
Issue Date:
2006
URI:
http://hdl.handle.net/10541/72546
PubMed ID:
16739317
Type:
Article
Language:
en
ISSN:
0250-7005
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorAl-Mowallad, Abdul Fattah-
dc.contributor.authorCarr, Trevor F-
dc.contributor.authorAl-Qouzi, Abdullah-
dc.contributor.authorLi, Chenggang-
dc.contributor.authorByers, Richard J-
dc.contributor.authorKumar, Shant-
dc.date.accessioned2009-07-06T10:51:22Z-
dc.date.available2009-07-06T10:51:22Z-
dc.date.issued2006-
dc.identifier.citationPlasma CD105, TGFbeta-1, TGFbeta-3 and the ligand/receptor complexes in children with acute lymphoblastic leukaemia., 26 (1B):543-7 Anticancer Res.en
dc.identifier.issn0250-7005-
dc.identifier.pmid16739317-
dc.identifier.urihttp://hdl.handle.net/10541/72546-
dc.description.abstractThe role of angiogenesis in solid tumours is well recognised, but its importance in haematological malignancies is less well understood. In leukaemia, mainly the determination of microvascular density utilising immunohistochemistry in the bone marrow trephines and the measurement of soluble angiogenic factors have led to the recognition that angiogenesis may be important in leukaemia as well. In this study, the soluble form of the endothelial cell activation/proliferation (i.e., angiogenesis) marker CD105 and its ligands TGFbeta-1 and -3, as well as the ligand/receptor complexes in plasma from children with acute lymphoblastic leukaemia (ALL) were quantified. The plasma level of CD105 was significantly higher in patients with common ALL compared to controls, while the TGFbeta-3 level was lower in patients. Neither the CD105 or TGFbeta-3 levels were of prognostic value, nor did they correlate with any of the known prognostic indicators, such as white blood cell counts. There were no significant differences between the plasma levels of any of the other parameters, such as TGFbeta-1 or the ligand receptor complexes, in children with leukaemia compared to controls. Our results support the role of angiogenesis in leukaemia and suggest that anti-angiogenesis may be a therapeutic target in leukaemia.en
dc.language.isoenen
dc.subjectLeukaemia Lymphomaen
dc.subject.meshAntigens, CD-
dc.subject.meshChild-
dc.subject.meshHumans-
dc.subject.meshImmunohistochemistry-
dc.subject.meshLigands-
dc.subject.meshPrecursor Cell Lymphoblastic Leukemia-Lymphoma-
dc.subject.meshPredictive Value of Tests-
dc.subject.meshPrognosis-
dc.subject.meshReceptors, Cell Surface-
dc.subject.meshTransforming Growth Factor beta-
dc.subject.meshTransforming Growth Factor beta1-
dc.subject.meshTransforming Growth Factor beta3-
dc.titlePlasma CD105, TGFbeta-1, TGFbeta-3 and the ligand/receptor complexes in children with acute lymphoblastic leukaemia.en
dc.typeArticleen
dc.contributor.departmentDivision of Laboratory and Regenerative Medicine, The University of Manchester, UK.en
dc.identifier.journalAnticancer Researchen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.